Fulgent Genetics Past Earnings Performance
Past criteria checks 0/6
Fulgent Genetics's earnings have been declining at an average annual rate of -28.1%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-28.1%
Earnings growth rate
-28.9%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 6.5% |
| Return on equity | -15.2% |
| Net Margin | -59.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Sep 25Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Sep 09Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio
Jul 17
Fulgent Genetics: Growth Is Returning
Jun 06Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
May 10Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 07Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09Fulgent Genetics: Sell Volatility
Jan 26Revenue & Expenses Breakdown
How Fulgent Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 278 | -165 | 130 | 49 |
| 30 Jun 24 | 291 | -163 | 128 | 47 |
| 31 Mar 24 | 288 | -166 | 126 | 43 |
| 31 Dec 23 | 289 | -168 | 128 | 41 |
| 30 Sep 23 | 286 | -64 | 121 | 38 |
| 30 Jun 23 | 307 | -49 | 135 | 35 |
| 31 Mar 23 | 365 | -26 | 142 | 33 |
| 31 Dec 22 | 619 | 143 | 144 | 29 |
| 30 Sep 22 | 803 | 272 | 141 | 28 |
| 30 Jun 22 | 925 | 392 | 118 | 26 |
| 31 Mar 22 | 953 | 461 | 96 | 25 |
| 31 Dec 21 | 993 | 507 | 75 | 24 |
| 30 Sep 21 | 1,036 | 569 | 58 | 21 |
| 30 Jun 21 | 910 | 493 | 48 | 18 |
| 31 Mar 21 | 773 | 417 | 40 | 15 |
| 31 Dec 20 | 422 | 214 | 30 | 12 |
| 30 Sep 20 | 135 | 48 | 21 | 9 |
| 30 Jun 20 | 44 | 3 | 15 | 7 |
| 31 Mar 20 | 35 | 0 | 13 | 7 |
| 31 Dec 19 | 33 | 0 | 12 | 7 |
| 30 Sep 19 | 30 | -2 | 11 | 6 |
| 30 Jun 19 | 25 | -4 | 11 | 6 |
| 31 Mar 19 | 22 | -6 | 10 | 6 |
| 31 Dec 18 | 21 | -6 | 10 | 6 |
| 30 Sep 18 | 20 | -5 | 10 | 5 |
| 30 Jun 18 | 19 | -6 | 10 | 5 |
| 31 Mar 18 | 18 | -5 | 10 | 5 |
| 31 Dec 17 | 19 | -3 | 9 | 4 |
| 30 Sep 17 | 20 | 0 | 9 | 4 |
| 30 Jun 17 | 21 | -5 | 8 | 4 |
| 31 Mar 17 | 20 | -13 | 7 | 4 |
| 31 Dec 16 | 18 | -14 | 7 | 4 |
| 30 Sep 16 | 15 | -22 | 9 | 6 |
| 30 Jun 16 | 13 | -15 | 7 | 5 |
| 31 Mar 16 | 11 | -6 | 7 | 5 |
| 31 Dec 15 | 10 | -5 | 5 | 4 |
| 31 Dec 14 | 1 | -1 | 1 | 1 |
Quality Earnings: FLGT is currently unprofitable.
Growing Profit Margin: FLGT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FLGT is unprofitable, and losses have increased over the past 5 years at a rate of 28.1% per year.
Accelerating Growth: Unable to compare FLGT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLGT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).
Return on Equity
High ROE: FLGT has a negative Return on Equity (-15.15%), as it is currently unprofitable.